Xeris Biopharma (NASDAQ:XERS) is a specialty biopharmaceutical company focused on the development and commercialization of ready-to-use injectable and infusible drug formulations. Headquartered in Chicago, the company leverages its proprietary formulation technology to create therapies that offer improved convenience, stability and patient compliance compared with traditionally compounded or reconstituted products. Since its founding, Xeris Biopharma has sought to address unmet medical needs in endocrinology and other therapeutic areas by simplifying the delivery of critical medications.
The company’s lead product, Gvoke®, is an FDA-approved glucagon injection designed for the treatment of severe hypoglycemia in people with diabetes. Gvoke is offered in two formats—a pre-filled syringe and a pre-filled auto-injector pen—both ready to use without reconstitution, enabling faster and more reliable administration in emergency situations. In addition to Gvoke, Xeris has secured approval for Brixadi®, a buprenorphine extended-release injection for the treatment of opioid use disorder. These commercial products are supported by a dedicated sales and marketing organization that serves healthcare professionals and patients across the United States.
At the core of Xeris Biopharma’s pipeline is its proprietary Polymer-Enhanced Sustained-Release (PESR) technology, which stabilizes peptides and proteins in non-aqueous formulations. This platform is being applied to a range of both licensed and in-house assets, including novel formulations of existing hormones and other therapeutics. Through strategic partnerships and licensing agreements, Xeris is also advancing programs in endocrinology, pain management and rare diseases, with plans to expand into international markets pending regulatory approvals.
Under the leadership of President and Chief Executive Officer Paul Tetlow, Xeris Biopharma continues to invest in research and development, manufacturing capabilities and commercial infrastructure. The company operates a state-of-the-art manufacturing facility and collaborates with contract manufacturing organizations to ensure supply chain robustness. With a pipeline of next-generation formulations and an established commercial foothold, Xeris Biopharma aims to deliver innovative, patient-centric therapies that simplify dosing and improve health outcomes globally.
